Friday, 16 October 2026European Markets

METABOLIC EXPLORER Stock Was 31.81% Up Today

Loading stream...

(vianews) - the market ended the session with metabolic explorer (metex.pa) rising 31.81% to €0.49 on monday, following the last session's downward trend. cac 40 dropped 0.03% to €7,589.96, following the last session's upward trend on what was a somewhat bearish trend trading session today.

metabolic explorer's last close was €0.37, 73.89% below its 52-week high of €1.42.

about metabolic explorer

metabolic explorer s.a., a biological chemistry company, engages in the development and industrialization of industrial fermentation processes as alternatives to petrochemical processes worldwide. the company also offers propanediol, butyric acid, butyric acid, glycolic acid, amino acid, and l-valine. its products are used in the formulation of cosmetics, textiles, polymer, animal nutrition, and health products or as intermediates for the synthesis of biomaterials. the company was incorporated in 1999 and is based in saint-beauzire, france.

earnings per share

as for profitability, metabolic explorer has a trailing twelve months eps of €-0.98.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -42.82%.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, metabolic explorer's stock is considered to be overbought (>=80).

volatility

metabolic explorer's last week, last month's, and last quarter's current intraday variation average was a negative 1.13%, a positive 0.39%, and a positive 4.67%.

metabolic explorer's highest amplitude of average volatility was 2.81% (last week), 3.65% (last month), and 4.67% (last quarter).

moving average

metabolic explorer's value is way higher than its 50-day moving average of €0.38 and way below its 200-day moving average of €0.69.

volume

today's last reported volume for metabolic explorer is 732171 which is 401.25% above its average volume of 146067.

more news about metabolic explorer (metex.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com